Evolved AAV Capsids for Gene Therapy of CLN2 Disease

被引：0
|
作者：
Tecedor, Luis [1 ]
Chen, Yong Hong [1 ]
Ranum, Paul T. [1 ]
Megan, Keiser S. [1 ]
Leib, David E. [1 ]
Cheng, Congsheng [1 ]
Lysenko, Elena [1 ]
Davidson, Beverly L. [1 ]
机构：
[1] Childrens Hosp Philadelphia, Perelman Ctr Cellular & Mol Therapy, Philadelphia, PA USA
来源：
MOLECULAR THERAPY | 2022年 / 30卷 / 04期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
266
引用
收藏
页码：128 / 129
页数：2
相关论文
共 50 条
  • [21] Intrafamilial variability in late-onset CLN2 disease
    Goobie, Sharan
    Bujold, Jillian
    Dyack, Sarah
    MOLECULAR GENETICS AND METABOLISM, 2020, 129 (02) : S66 - S67
  • [22] OCT Biomarkers in Ocular CLN2 Disease in Patients Treated With Intraventricular Enzyme Replacement Therapy
    Huang, Wei Chieh
    Ohnsman, Christina M.
    Atiskova, Yevgeniya
    Falabella, Paulo
    Spitzer, Martin S.
    Schulz, Angela
    Dulz, Simon
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (08)
  • [23] Intracerebrovascular enzyme replacement therapy for CLN2 disease: A collaborative, multi-disciplinary approach
    Pires-Barracosa, Naomi
    Movsesyan, Nina
    Truong, Nicole
    Olaya, Joffre
    See, Susan
    Adlard, Kathleen
    Stockton, Winifred
    Wang, Raymond
    MOLECULAR GENETICS AND METABOLISM, 2018, 123 (02) : S117 - S117
  • [24] Intracerebroventricular gene therapy that delays neurological disease progression is associated with selective preservation of retinal ganglion cells in a canine model of CLN2 disease
    Whiting, Rebecca E. H.
    Jensen, Cheryl A.
    Pearce, Jacqueline W.
    Gillespie, Lauren E.
    Bristow, Daniel E.
    Katz, Martin L.
    EXPERIMENTAL EYE RESEARCH, 2016, 146 : 276 - 282
  • [25] Intravitreal gene therapy preserves retinal function in a canine model of CLN2 neuronal ceroid lipofuscinosis
    Kick, Grace Robinson
    Whiting, Rebecca E. H.
    Ota-Kuroki, Juri
    Castaner, Leilani J.
    Morgan-Jack, Brandie
    Sabol, Julianna C.
    Meiman, Elizabeth J.
    Ortiz, Francheska
    Katz, Martin L.
    EXPERIMENTAL EYE RESEARCH, 2023, 226
  • [26] Novel Neurotropic and Myotropic AAV Capsids for Translational Gene Therapy Applications
    Garza, Irvin T.
    Ramesh, Vijayashree
    Kang, Hye Ri
    Lykken, Erik A.
    Takar, Mehmet
    Rioux, Matthew C.
    Kumar, Ashwani
    Kunach, Peter
    Singh, Ruhar
    Kieffer, Daniel J.
    Trygg, Cynthia B.
    Xing, Chao
    Joachimiak, Lukasz
    Braun, Stephen
    Gray, Steven J.
    MOLECULAR THERAPY, 2024, 32 (04) : 116 - 116
  • [27] Comparative study of liver gene therapy with AAV vectors based on endogenous and engineered AAV capsids
    Wang, L.
    Bell, P.
    Somanathan, S.
    Wang, Q.
    He, Z.
    Yu, H.
    McMenamin, D.
    Goode, T.
    Calcedo, R.
    Wilson, J. M.
    HUMAN GENE THERAPY, 2015, 26 (10) : A101 - A101
  • [28] CLN2 Disease (Classic Late Infantile Neuronal Ceroid Lipofuscinosis)
    Kohlschuetter, Alfried
    Schulz, Angela
    PEDIATRIC ENDOCRINOLOGY REVIEWS PER, 2016, 13 : 682 - 688
  • [29] Extraneuronal pathology in a canine model of CLN2 neuronal ceroid lipofuscinosis after intracerebroventricular gene therapy that delays neurological disease progression
    Katz, M. L.
    Johnson, G. C.
    Leach, S. B.
    Williamson, B. G.
    Coates, J. R.
    Whiting, R. E. H.
    Vansteenkiste, D. P.
    Whitney, M. S.
    GENE THERAPY, 2017, 24 (04) : 215 - 223
  • [30] Clinical Pharmacokinetics and Pharmacodynamics of Cerliponase Alfa, Enzyme Replacement Therapy for CLN2 Disease by Intracerebroventricular Administration
    Kim, Aryun
    Grover, Anita
    Hammon, Kevin
    de Hart, Greg
    Slasor, Peter
    Cherukuri, Anu
    Ajayi, Temitayo
    Jacoby, David
    Schulz, Angela
    Specchio, Nicola
    de Los Reyes, Emily
    Gissen, Paul
    Henshaw, Joshua W.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2021, 14 (02): : 635 - 644
12345